Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2020

01.09.2020 | editorial

Treatment of advanced melanoma

verfasst von: Prof. Dr. med. univ. Van Anh Nguyen

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

Over the past decade the treatment of advanced melanoma has been revolutionized by the approval of new therapeutic agents, including BRAF (v-raf murine sarcoma viral oncogene homolog B1) and MEK (Mitogen-activated protein kinase) inhibitors, cytotoxic T‑lymphocyte-associated antigen 4 (CTLA-4) and programmed cell-death protein 1 (PD-1) blocking antibodies, as well as a modified oncolytic herpes virus that is given intratumourally. These changes in the treatment landscape have dramatically improved objective response rates, progression-free survival and overall survival for patients. Specifically, the overall survival of patients with metastatic melanoma has improved from 9 months before 2011 to ongoing long-term tumour control in a subset of patients. …
Metadaten
Titel
Treatment of advanced melanoma
verfasst von
Prof. Dr. med. univ. Van Anh Nguyen
Publikationsdatum
01.09.2020
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2020
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-020-00634-9

Weitere Artikel der Ausgabe 3/2020

memo - Magazine of European Medical Oncology 3/2020 Zur Ausgabe